Support Line: 0300 373 8500
This study has two parts. The first measures the efficacy of Iopofosine I 131 in patients with some B-cell cancers. The second part focusses in particular on WM patients who have received at least two lines of treatment previously.
Iopofosine I 131 is a type of targeted treatment known as a radiotherapeutic. It delivers radiation direct to certain cancer cells by targeting them, and has been shown to be effective in other types of cancer.
This study is on-going but currently closed to recruitment.
• Confirmed diagnosis of WM (people diagnosed with LPL may be eligible)
• Part A of the study – Previously treated with standard therapy
• Part B of the study – Received two prior lines of treatment
